Skip to content

Webinar: Human iPSCs & High-Throughput Screening for Drug Discovery

Ncardia author image

By Oscar Bartulos, PhD

Fully Automated Phenotypic High-Throughput Screening in a Model of Hypertrophic Cardiomyopathy

One of the pillars of drug discovery programs is the selection of a predictive preclinical model. The system, stimulus and readout should be of the highest possible clinical relevance to develop a good predictive model and help decreasing the drug attrition rate.In this webinar we explain how patient-specific and genetically modified iPSC-derived cells can be utilized to develop relevant assays for high-throughput phenotypic screening. We present how iPSC-derived cardiomyocytes can be applied to perform fully automated phenotypic high-throughput screening in a model of hypertrophic cardiomyopathy.

In this webinar you will learn:

  • How to select relevant cellular models suitable for phenotypic high-throughput screening

  • Parameters to be considered for your assay development

  • Key considerations for lead selection and validation


Fill in the form below to watch the replay: